全球首款胆管癌靶向疗法—培米替尼pemigatinib

Pemigatinib is a potent and selective oral inhibitor of FGFR subtypes 1/2/3. It is the first targeted therapy for cholangiocarcinoma approved by the United States, Japan, and the European Union. It can prevent the growth and spread of tumor cells by blocking FGFR2 in tumor cells. The US FDA has approved it for the treatment of patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.

A total of 108 patients with cholangiocarcinoma were enrolled in the FIGHT-202 study and received oral treatment with pemigatinib 13.5 mg. Trial results show: pemigatinib treatment showed durable tumor response. The objective response rate (ORR) confirmed based on IRRC assessment was 37%; the median duration of response (DOR) was 8.1 months; the median progression-free survival (PFS) was 7.0 months; the median overall survival (OS) was 17.5 months; the mOS of responders vs non-responders was 30.1 months vs 13.7 months respectively. From the above test data, it can be seen that pemigatinib has a significant therapeutic effect. This drug can prolong the survival period of patients, improve the remission rate, extend the duration of remission, improve the patient's quality of life, and have a positive effect on the patient's condition. The launch of pemetinib has brought new treatment options to many patients with cholangiocarcinoma.

The above is an introduction to pemigatinib. If patients want to know more drug information about pemigatinib (such as usage, precautions, drug prices, purchase channels, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: